Kite Pharma Inc. a major player in autologous chimeric antigen receptor T-cell (CAR-T) therapies aimed at B-cell malignancies, is expecting late-stage data for its lead candidate, KTE-C19, in diffuse large B-cell lymphoma very soon.
The company indicated during its second-quarter earnings call that it will be getting top-line data from the ZUMA-1 study of...